FDA Highlights: Prophylactic anastrozole reduces breast cancer development by 53 percent among high risk women
by Bruce Sylvester – Prophylactic use of the breast cancer drug anastrozole for five years reduced by 53% the development of breast cancer in post-menopausal women at high… read more.